Literature DB >> 21261806

Mechanisms underlying FeCl3-induced arterial thrombosis.

A Eckly1, B Hechler, M Freund, M Zerr, J-P Cazenave, F Lanza, P H Mangin, C Gachet.   

Abstract

BACKGROUND: The FeCl(3)-induced vascular injury model is widely used to study thrombogenesis in vivo, but the processes leading to vascular injury and thrombosis are poorly defined.
OBJECTIVES: The aim of our study was to better characterize the mechanisms of FeCl(3)-induced vascular injury and thrombus formation, in order to evaluate the pathophysiological relevance of this model.
METHODS: FeCl(3) was applied at different concentrations (from 7.5% to 20%) and for different time periods (up to 5 min) to mouse carotid or mesenteric arteries.
RESULTS: Under all the conditions tested, ultrastructural analysis revealed that FeCl(3) diffused through the vessel wall, resulting in endothelial cell denudation without exposure of the inner layers. Hence, only the basement membrane components were exposed to circulating blood cells and might have contributed to thrombus formation. Shortly after FeCl(3) application, numerous ferric ion-filled spherical bodies appeared on the endothelial cells. Interestingly, platelets could adhere to these spheres and form aggregates. Immunogold labeling revealed important amounts of tissue factor at their surface, suggesting that these spheres may play a role in thrombin generation. In vitro experiments indicated that FeCl(3) altered the ability of adhesive proteins, including collagen, fibrinogen and von Willebrand factor, to support platelet adhesion. Finally, real-time intravital microscopy showed no protection against thrombosis in GPVI-immunodepleted and β(1)(-/-) mice, suggesting that GPVI and β(1) integrins, known to be involved in initial platelet adhesion and activation, do not play a critical role in FeCl(3)-induced thrombus formation.
CONCLUSION: This model should be used cautiously, in particular to study the earliest stage of thrombus formation.
© 2011 International Society on Thrombosis and Haemostasis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21261806     DOI: 10.1111/j.1538-7836.2011.04218.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  63 in total

1.  Microvascular anastomosis guidance and evaluation using real-time three-dimensional Fourier-domain Doppler optical coherence tomography.

Authors:  Yong Huang; Zuhaib Ibrahim; Dedi Tong; Shan Zhu; Qi Mao; John Pang; Wei Ping Andree Lee; Gerald Brandacher; Jin U Kang
Journal:  J Biomed Opt       Date:  2013-11       Impact factor: 3.170

2.  Resolving the multifaceted mechanisms of the ferric chloride thrombosis model using an interdisciplinary microfluidic approach.

Authors:  Jordan C Ciciliano; Yumiko Sakurai; David R Myers; Meredith E Fay; Beatrice Hechler; Shannon Meeks; Renhao Li; J Brandon Dixon; L Andrew Lyon; Christian Gachet; Wilbur A Lam
Journal:  Blood       Date:  2015-04-30       Impact factor: 22.113

3.  Multifunctional biomedical imaging in physiological and pathological conditions using a NIR-II probe.

Authors:  Kangquan Shou; Chunrong Qu; Yao Sun; Hao Chen; Si Chen; Lei Zhang; Haibo Xu; Xuechuan Hong; Aixi Yu; Zhen Cheng
Journal:  Adv Funct Mater       Date:  2017-04-24       Impact factor: 18.808

4.  Hemostatic disorders in a JAK2V617F-driven mouse model of myeloproliferative neoplasm.

Authors:  Lamia Lamrani; Catherine Lacout; Véronique Ollivier; Cécile V Denis; Elizabeth Gardiner; Benoit Ho Tin Noe; William Vainchenker; Jean-Luc Villeval; Martine Jandrot-Perrus
Journal:  Blood       Date:  2014-06-20       Impact factor: 22.113

5.  Role of the CD39/CD73 Purinergic Pathway in Modulating Arterial Thrombosis in Mice.

Authors:  Roman Covarrubias; Elena Chepurko; Adam Reynolds; Zachary M Huttinger; Ryan Huttinger; Katherine Stanfill; Debra G Wheeler; Tatiana Novitskaya; Simon C Robson; Karen M Dwyer; Peter J Cowan; Richard J Gumina
Journal:  Arterioscler Thromb Vasc Biol       Date:  2016-07-14       Impact factor: 8.311

6.  Comparative anti-thrombotic activity and haemorrhagic adverse effect of nattokinase and tissue-type plasminogen activator.

Authors:  Haiyu Guo; Young-Hwan Ban; Yeseul Cha; Eun Suk An; Jieun Choi; Da Woom Seo; Dongsun Park; Ehn-Kyoung Choi; Yun-Bae Kim
Journal:  Food Sci Biotechnol       Date:  2019-05-27       Impact factor: 2.391

7.  A plasmin-activatable thrombin inhibitor reduces experimental thrombosis and assists experimental thrombolysis in murine models.

Authors:  W P Sheffield; L J Eltringham-Smith; S Gataiance; V Bhakta
Journal:  J Thromb Thrombolysis       Date:  2015-05       Impact factor: 2.300

8.  Xenotropic and polytropic retrovirus receptor 1 regulates procoagulant platelet polyphosphate.

Authors:  Reiner K Mailer; Mikel Allende; Marco Heestermans; Michaela Schweizer; Carsten Deppermann; Maike Frye; Giordano Pula; Jacob Odeberg; Mathias Gelderblom; Stefan Rose-John; Albert Sickmann; Stefan Blankenberg; Tobias B Huber; Christian Kubisch; Coen Maas; Stepan Gambaryan; Dmitri Firsov; Evi X Stavrou; Lynn M Butler; Thomas Renné
Journal:  Blood       Date:  2021-03-11       Impact factor: 22.113

9.  Allosterism-based simultaneous, dual anticoagulant and antiplatelet action: allosteric inhibitor targeting the glycoprotein Ibα-binding and heparin-binding site of thrombin.

Authors:  A Y Mehta; B M Mohammed; E J Martin; D F Brophy; D Gailani; U R Desai
Journal:  J Thromb Haemost       Date:  2016-02-16       Impact factor: 5.824

10.  Red blood cells mediate the onset of thrombosis in the ferric chloride murine model.

Authors:  Justin D Barr; Anil K Chauhan; Gilbert V Schaeffer; Jessica K Hansen; David G Motto
Journal:  Blood       Date:  2013-01-23       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.